<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>191-DOLUTEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOLUTEGRAVIR" rxcui="1433868">
<ATC code="J05AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of dolutegravir by increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-in case of resistance to the class of integrase inhibitors</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>191-DOLUTEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOLUTEGRAVIR" rxcui="1433868">
<ATC code="J05AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METFORMIN" rxcui="6809">
<ATC code="A10BA02" />
<ATC code="A10BD13" />
<ATC code="A10BD11" />
<ATC code="A10BD05" />
<ATC code="A10BD03" />
<ATC code="A10BD10" />
<ATC code="A10BD07" />
<ATC code="A10BD02" />
<ATC code="A10BD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of metformin by the dolutegravir and of its undesirable effects of the lactic acidosis type</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>With the patient having moderate renal insufficiency (stage 3a, clearance of the creatinin between 45 and 59 ml/min), clinical and biological monitoring, and possible adjustment of the dosage of metformin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>191-DOLUTEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOLUTEGRAVIR" rxcui="1433868">
<ATC code="J05AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the St Johns wort.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
